S 1096 · Preserve Access to Affordable Generics and Biosimilars Act
Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
- Introduced
- Mar 24, 2025
- Latest action
- Apr 10, 2025
- Sponsor
- Sen. Amy Klobuchar [D-MN]
- Policy area
- Health
- Cosponsors
- 8
Summary
Preserve Access to Affordable Generics and Biosimilars Act This bill prohibits parties from entering into any agreement that resolves or settles a patent claim related to the sale of a drug or biological product and that has anticompetitive effects. Such an agreement is presumed to have anticompetitive effects if the filer of a generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar. An agreement is exempt if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a U.S. patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects. The bill provides for enforcement by the Federal Trade Commission (FTC). Violators are subject to penalties including the forfeiture of the 180-day marketing exclusivity period for a generic drug. Additionally, when a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC and the Department of Justice concerning the agreement contains the complete agreement and any related agreements, including descriptions of any oral agreements or representations.
Recent actions
- Apr 10, 2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
- Apr 10, 2025 Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
- Apr 10, 2025 Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
- Apr 3, 2025 Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Mar 24, 2025 Read twice and referred to the Committee on the Judiciary.
- Mar 24, 2025 Introduced in Senate
Votes
No recorded votes are available for this bill.